Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic target for managing metabolic conditions. These naturally occurring hormones are secreted by the gut in response to food intake, stimulating insulin secretion and suppressing glucagon release. GLP-1 peptides demonstrate promising therapeutic efficacy in treating type 2